At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed aggressive diffuse large B-cell lymphoma
- ✓CD20-positive disease
- ✓Age-adjusted International Prognostic Index II or III (defined by Karnofsky 10–70%, LDH >200 U/L, or stage III/IV)
- ✓PET-avid measurable disease
- ✕Prior chemotherapy for malignancy
- ✕Prior biologic therapy for malignancy
- ✕Prior radiotherapy for malignancy
- ✕Prior surgery for malignancy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Risk-Adapted Therapy for Patients With Untreated Age-Adjusted International Prognostic Index II or III Diffuse Large B Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating filgrastim, rituximab, and 9 other interventions for Lymphoma. Completed, enrolled 98 participants across 1 site.
Detailed Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy, total-body irradiation, and peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving chemotherapy with rituximab followed by combination chemotherapy with or without rituximab, total-body irradiation, and peripheral stem cell transplant works in treating patients with lymphoma.